查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046326

肝母細胞瘤治療市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

Hepatoblastoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Treatment, By End User By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肝母細胞瘤治療市場預計將從 2025 年的 3.6998 億美元大幅成長至 2031 年的 5.7836 億美元，複合年成長率為 7.73%。

這個專業市場涵蓋了兒童最常見原發性肝癌的多種綜合治療方法，包括新輔助Cisplatin化療、手術切除和原位肝移植。市場成長主要得益於風險分層系統的持續發展以及兒童's Oncology Group）等組織所製定的國際治療方案的標準化。這些措施顯著提高了無事件存活率。此外，高容量兒童肝膽胰外科中心的集中診療使得更積極、更成功的腫瘤切除成為可能，從而增加了對先進的圍手術全期管理和輔助性治療的需求。儘管取得了這些臨床進展，含鉑類藥物的長期毒性，特別是永久性聽力喪失和心臟毒性的高發生率，仍然是市場有效性的主要障礙。這些不利事件需要昂貴的長期後續觀察和廣泛的支持性治療，增加了治療的整體負擔。準確的流行病學數據對於在這個特殊治療領域進行有效的資源分配仍然至關重要。例如，美國癌症協會估計，到2025年，美國將有9550名0至14歲的兒童被診斷出患有癌症，這凸顯了針對罕見兒童固體癌（例如肝母細胞瘤）的標靶治療的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 3.6998億美元
市場規模：2031年 5.7836億美元
複合年成長率：2026-2031年 7.73%
成長最快的細分市場 外科手術
最大的市場 北美洲

市場促進因素

多模態和個人化治療策略的日益普及正在從根本上改變市場格局，其關注點不僅在於根除腫瘤，還在於減輕治療相關的長期毒性。隨著患者存活率的提高，臨床重點正轉向減少含鉑類藥物類化療相關的持續性副作用，例如耳毒性，這推動了專業支持治療的商業性。硫代硫酸鈉製劑的強勁市場表現清晰地反映了這一趨勢。根據Fennec Pharmaceuticals於2025年11月發布的2025年第三季財報，聽力保護劑PEDMARK的淨銷售額達到約1,250萬美元，較去年同期成長79%。這凸顯了隨著治療方法的不斷發展，業界致力於提供全面的生存期護理。此外，標準化國際治療方案的引入，透過將分散的患者數據整合到統一的全球註冊庫中，正在加速臨床進展。主要合作研究團隊之間的風險分層標準標準化，使得先前難以進行的大規模研究成為可能，尤其針對這種罕見惡性腫瘤。例如，2025年10月，肝母細胞瘤資源網路報告稱，國際兒童肝腫瘤試驗（PHITT）已成功在全球招募了1000多名兒童肝癌患者，為未來的治療指南奠定了重要的實證基礎。這種全球合作對於應對疾病的廣泛影響至關重要。根據美國國立衛生研究院（NIH）於2025年8月發布的《肝母細胞瘤全球負擔》報告，2021年全球共記錄了4048例新發肝母細胞瘤病例，凸顯了開展國際協調努力的必要性。

市場挑戰

含鉑類藥物的長期毒性，尤其是永久性聽力喪失和心臟毒性的高發生率，是全球肝母細胞瘤治療市場擴張的主要障礙。這項挑戰阻礙了市場成長，因為醫療機構的資金重心從引入主要治療方案轉移到成本高昂的長期後續觀察和持續支持治療。終身管理這些不利事件的需求顯著增加了每位患者的總治療費用，導致報銷模式出現摩擦，並限制了分配給積極藥物治療方案的預算。因此，緩解治療相關併發症的經濟負擔降低了目前標準治療方法的提案，並導致支付方在資助強化治療方面猶豫不決。鑑於肝母細胞瘤患者群體的特殊性，以及疾病本身的罕見性導致資源分配本就受限，這個問題尤其突出。根據美國癌症協會預測，到2025年，肝癌和肝內膽管癌將約占美國0至14歲兒童所有癌症診斷的2%。這種有限的流行病學規模意味著，與毒性管理相關的高成本對整體市場估值產生了不成比例的影響，進而阻礙了高風險、嚴重副作用的高強度治療方案的廣泛應用。

市場趨勢

抗GPC3免疫療法的出現標誌著肝母細胞瘤治療市場的一次變革性轉變，它超越了傳統的化療，靶向在肝癌細胞中高表達的糖蛋白-3（glypican-3）。這一趨勢的特徵是嵌合體抗原受體（CAR）T細胞療法迅速展現出臨床療效，該療法旨在克服復發和難治性病例中常見的免疫抑制性腫瘤微環境。為了證明該治療方法的巨大潛力，AbelZeta Pharma於2024年6月宣布，其新型GPC3標靶CAR-T療法C-CAR031在進行性GPC3陽性肝腫瘤患者中取得了56.5%的客觀緩解率。這凸顯了其作為治療抗藥性惡性腫瘤的強效療法的有效性。同時，精準醫療和分子譜分析的日益普及，透過整合遺傳生物標記來指導高度個人化的治療策略，正在從根本上重塑風險分層。這種先進的方法正將市場從純粹的臨床分期系統轉向全面的基因組分析，使患者能夠接受標靶治療有效降低不必要的毒性，同時最大限度地延長生存期。近期機構研究也證實了這種方法的效用。根據丹娜-法伯癌症研究所2024年8月發布的《丹娜-法伯研究新聞》報告，對兒童癌症患者的基因組分析顯示，33%的患者至少攜帶一種與精準腫瘤臨床試驗方案相符的基因變異，這凸顯了先進分子診斷在最佳化複雜固態腫瘤治療方案方面的重要作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：肝母細胞瘤治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（烷化劑、抗生素、長春花生物鹼、抗代謝藥、其他）
    • 治療方法（手術、化療、標靶治療、放射線治療、消融治療等）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肝母細胞瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肝母細胞瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肝母細胞瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肝母細胞瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肝母細胞瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球肝母細胞瘤治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eureka Therapeutics.
  • Fennec Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Pfizer Inc.
  • AstraZeneca Plc
  • Boston Scientific Corporation
  • Nantong Haier's Pharmaceutical co. ltd
  • GSK plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18785

The Global Hepatoblastoma Treatment Market is projected to expand significantly, growing from USD 369.98 Million in 2025 to USD 578.36 Million by 2031, demonstrating a compound annual growth rate (CAGR) of 7.73%. This specialized market encompasses a range of multimodal therapies, including neoadjuvant cisplatin-based chemotherapy, surgical resection, and orthotopic liver transplantation, all aimed at managing the most common primary hepatic malignancy in children. The market's growth is largely propelled by the continuous evolution of risk-stratification systems and the standardization of international treatment protocols, such as those established by the Children's Oncology Group, which have markedly improved event-free survival rates. Furthermore, the centralization of care at high-volume pediatric hepatobiliary surgical centers enables more aggressive and successful tumor resections, thereby driving demand for advanced perioperative management and adjuvant therapies. Despite these clinical advancements, a significant hurdle to market efficacy is the high incidence of long-term platinum-induced toxicities, particularly permanent hearing loss and cardiotoxicity. These adverse effects necessitate costly longitudinal monitoring and extensive supportive care interventions, increasing the overall burden of treatment. Accurate epidemiological data remains crucial for effective resource allocation within this niche therapeutic landscape. For instance, the American Cancer Society estimates that 9,550 children aged 0 to 14 will be diagnosed with cancer in the United States in 2025, highlighting the critical need for targeted therapies for rare pediatric solid tumors like hepatoblastoma.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 369.98 Million
Market Size 2031USD 578.36 Million
CAGR 2026-20317.73%
Fastest Growing SegmentSurgery
Largest MarketNorth America

Market Driver

The increasing adoption of multimodal and personalized treatment strategies is fundamentally transforming the market by focusing not only on tumor eradication but also on mitigating long-term treatment-induced toxicities. As patient survival rates improve, clinical emphasis has shifted towards reducing permanent side effects from platinum-based chemotherapy, such as ototoxicity, which in turn has driven the commercial uptake of specialized supportive therapies. This trend is exemplified by the robust market performance of sodium thiosulfate formulations; according to Fennec Pharmaceuticals' 'Third Quarter 2025 Financial Results' in November 2025, net product sales for the otoprotective agent PEDMARK reached approximately $12.5 million, marking a significant 79% year-over-year increase, which underscores the industry's commitment to comprehensive survivorship care within evolving treatment regimens. Moreover, the implementation of standardized international care protocols is accelerating clinical progress by consolidating fragmented patient data into cohesive global registries. The unification of risk-stratification criteria across major cooperative groups has facilitated large-scale studies that were previously unfeasible for this rare malignancy. For instance, the Hepatoblastoma Resource Network reported in October 2025 that the Pediatric Hepatic International Tumor Trial (PHITT) has successfully enrolled over 1,000 children with liver cancers worldwide, establishing a critical evidence base for future therapeutic guidelines. This global coordination is vital for addressing the disease's extensive reach; the National Institutes of Health's 'Global Burden of Hepatoblastoma' report in August 2025 indicated 4,048 new cases of hepatoblastoma recorded globally in 2021, underscoring the necessity for synchronized international efforts.

Market Challenge

The high incidence of long-term platinum-induced toxicities, specifically permanent hearing loss and cardiotoxicity, presents a substantial obstacle to the expansion of the global hepatoblastoma treatment market. This challenge impedes market growth by diverting the financial focus of healthcare providers from the acquisition of primary therapeutics to costly longitudinal monitoring and ongoing supportive care interventions. The requirement for lifelong management of these adverse effects significantly escalates the total cost of care per patient, creating friction in reimbursement models and limiting the budget available for aggressive pharmacological protocols. Consequently, the economic burden associated with mitigating treatment-related disabilities complicates the value proposition of current standard-of-care regimens, leading to hesitation among payers regarding the funding of intensified therapies. This issue is particularly pronounced given the specialized nature of the patient population, where resource allocation is already constrained by the rarity of the condition. According to the American Cancer Society, liver and intrahepatic bile duct cancers are projected to account for approximately 2% of all cancer diagnoses in children aged 0 to 14 years in the United States in 2025. This limited epidemiological footprint means that the high costs linked to toxicity management disproportionately impact the overall market valuation, thereby hindering broader adoption of high-intensity treatments that carry elevated risks of severe side effects.

Market Trends

The emergence of Anti-GPC3 Immunotherapies signifies a transformative shift in the hepatoblastoma market, moving beyond conventional chemotherapy to target the Glypican-3 protein, which is highly expressed in hepatic tumor cells. This trend is characterized by the rapid clinical validation of Chimeric Antigen Receptor (CAR) T-cell therapies specifically designed to overcome the immunosuppressive tumor microenvironment prevalent in relapsed or refractory cases. Demonstrating the substantial potential of this modality, AbelZeta Pharma announced in June 2024 that its novel GPC3-targeted CAR-T therapy, C-CAR031, achieved an objective response rate of 56.5% in patients with advanced GPC3-positive liver tumors, highlighting its efficacy as a potent therapeutic alternative for resistant malignancies. Concurrently, the increasing Adoption of Precision Medicine and Molecular Profiling is fundamentally reshaping risk stratification by integrating genetic biomarkers to guide highly tailored therapeutic strategies. This advanced approach is moving the market beyond purely clinical staging systems toward comprehensive genomic analysis, ensuring that patients receive targeted interventions that effectively minimize unnecessary toxicity while simultaneously maximizing survival outcomes. This utility is evidenced by recent institutional research; according to the Dana-Farber Cancer Institute's 'Dana-Farber Research News' report in August 2024, genomic profiling of pediatric cancer patients revealed that 33% had at least one genetic variant matching a precision oncology trial protocol, underscoring the critical role of advanced molecular diagnostics in optimizing treatment selection for complex solid tumors.

Key Market Players

  • Eureka Therapeutics.
  • Fennec Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Pfizer Inc.
  • AstraZeneca Plc
  • Boston Scientific Corporation
  • Nantong Haier's Pharmaceutical co. ltd
  • GSK plc

Report Scope

In this report, the Global Hepatoblastoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatoblastoma Treatment Market, By Drug Class

  • Alkylating Agent
  • Antibiotics
  • Vinca Alkaloids
  • Antimetabolites
  • Others

Hepatoblastoma Treatment Market, By Treatment

  • Surgery
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Ablation Therapy
  • Others

Hepatoblastoma Treatment Market, By End User

  • Hospitals & Clinics
  • Ambulatory care Centers
  • Others

Hepatoblastoma Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatoblastoma Treatment Market.

Available Customizations:

Global Hepatoblastoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatoblastoma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Alkylating Agent, Antibiotics, Vinca Alkaloids, Antimetabolites, Others)
    • 5.2.2. By Treatment (Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, Ablation Therapy, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Hepatoblastoma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatoblastoma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Hepatoblastoma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Hepatoblastoma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End User

7. Europe Hepatoblastoma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatoblastoma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. France Hepatoblastoma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Hepatoblastoma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Hepatoblastoma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Hepatoblastoma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By End User

8. Asia Pacific Hepatoblastoma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hepatoblastoma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. India Hepatoblastoma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Hepatoblastoma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Hepatoblastoma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Hepatoblastoma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By End User

9. Middle East & Africa Hepatoblastoma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hepatoblastoma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Hepatoblastoma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Hepatoblastoma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End User

10. South America Hepatoblastoma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hepatoblastoma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Hepatoblastoma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Hepatoblastoma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hepatoblastoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eureka Therapeutics.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Fennec Pharmaceuticals Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. Cipla Limited
  • 15.6. Pfizer Inc.
  • 15.7. AstraZeneca Plc
  • 15.8. Boston Scientific Corporation
  • 15.9. Nantong Haier's Pharmaceutical co. ltd
  • 15.10. GSK plc

16. Strategic Recommendations

17. About Us & Disclaimer